Valion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) was the target of a significant increase in short interest during the month of September. As of September 30th, there was short interest totaling 87,968 shares, an increase of 128.9% from the September 15th total of 38,427 shares. Currently, 10.2% of the company’s shares are sold short. Based on an average daily trading volume, of 5,958,426 shares, the short-interest ratio is presently 0.0 days.
Valion Bio, Inc. Common Stock Trading Down 1.3%
NASDAQ VBIO opened at $1.53 on Wednesday. Valion Bio, Inc. Common Stock has a 52 week low of $1.47 and a 52 week high of $75.50. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.86 and a current ratio of 1.11. The stock’s 50 day moving average price is $3.35 and its two-hundred day moving average price is $13.26. The stock has a market capitalization of $1.36 million, a price-to-earnings ratio of -0.01 and a beta of 1.80.
Analysts Set New Price Targets
A number of analysts have recently commented on the company. Wall Street Zen raised Valion Bio, Inc. Common Stock to a “hold” rating in a research note on Saturday, September 5th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Valion Bio, Inc. Common Stock in a research note on Friday, July 17th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.
Valion Bio, Inc. Common Stock Company Profile
Tivic Health Systems Inc operates as a health tech company, focuses on developing and commercializing bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, such as BestBuy and FSAStore and through distributors. Tivic Health Systems, Inc was incorporated in 2016 and is headquartered in Hayward, California.
Featured Articles
- Five stocks we like better than Valion Bio, Inc. Common Stock
- Quantum BioPharma’s Phase 2 Shows Where Biotech Value Actually Gets Built
- Albertsons Is Betting on a Turnaround—But Will It Pay Off?
- Venezuela’s Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit
- PepsiCo’s Earnings Beat Masks a Bigger Problem With Its North American Business
Receive News & Ratings for Valion Bio Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valion Bio Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
